Aug 6, 2026 Publication of the Interim Report for the First Half 2026 (after 5:00 PM CEST) Genmab will publish its Interim Report for the First Half 2026 on August 6, 2026, after 5:00 pm CEST.A conference call to discuss Genmab’s Second Quarter 2026 Financial Results will be held the same day at 6:00 pm CEST / 12:00 pm EDT.Register for the call.To join the call please use the registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN. Listen to the webcast Nov 5, 2026 Publication of the Interim Report for the First Nine Months 2026 (after 5:00 PM CET) May 7, 2026 Publication of the Interim Report for the First Quarter 2026 (after 5:00 PM CEST) Genmab held a conference call to discuss its Q1 2026 financial results on May 7, 2026. Listen to the webcast replay Supporting Materials Interim Report for the First Quarter of 2026 769.2 KB Genmab First Quarter 2026 Financial Results Presentation 1 MB Mar 19, 2026 Annual General Meeting 2026 The Annual General Meeting 2026 will take place on Thursday, March 19, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark. Register here. Mar 11, 2026 1:30 PM EDT Barclays 28th Annual Global Healthcare Conference Listen to the webcast Mar 10, 2026 8:40 AM EDT Leerink Global Healthcare Conference Listen to the webcast Mar 3, 2026 9:10 AM EST TD Cowen 46th Annual Healthcare Conference Listen to the webcast Feb 17, 2026 Publication of the Annual Report for 2025 (after 5:00 PM CET) Genmab will hold a conference call to discuss its 2025 financial results at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST on February 17, 2026 Listen to the webcast Supporting Materials Genmab 2025 Annual Report 12.7 MB Genmab 2025 Full Year Financial Results Presentation 1.1 MB Jan 13, 2026 3:45 PM PST 44th Annual J.P. Morgan Healthcare Conference Listen to the webcast Supporting Materials JP Morgan 2026 Presentation 924.6 KB Dec 31, 2025 Financial Calendar Year End Dec 11, 2025 11:00 AM EST 2025 R&D Update and ASH Data Review Genmab hosted its 2025 R&D Update and ASH Data Review virtually on Thursday, December 11, 2025.This meeting was not an official program of the ASH Annual Meeting. Listen to the webcast replay Supporting Materials Genmab R&D Update and ASH Data Review - December 2025 2 MB Dec 4, 2025 9:45 AM EST Citi 2025 Global Healthcare Conference Listen to the webcast Nov 19, 2025 1:00 PM CET Jefferies Healthcare Conference Fireside Chat with Chief Executive Officer, Jan van de Winkel, and Chief Financial Officer, Anthony Pagano. Listen to Webcast Nov 6, 2025 Publication of the Interim Report for the First Nine Months 2025 (after 5:00 PM CET) Listen to the webcast replay Supporting Materials Interim Report for the First Nine Months of 2025 675.1 KB Genmab First Nine Months 2025 Financial Results Presentation 1.1 MB Sep 29, 2025 7:00 AM EDT Genmab's Proposed Acquisition of Merus Listen to the Webcast Replay Supporting Materials Genmab’s Proposed Acquisition of Merus_September 29, 2025 1.1 MB Sep 23, 2025 12:35 PM CEST Bank of America 2025 Global Healthcare Conference Listen to the Webcast Sep 9, 2025 7:45 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat with Chief Executive Officer Jan van de Winkel and Chief Financial Officer Anthony Pagano. Listen to the webcast Aug 7, 2025 Publication of the Interim Report for the First Half 2025 (after 5:00 PM CEST) On August 7, Genmab announced its financial results for the first half of 2025. Listen to the webcast Supporting Materials Interim Report for the First Half of 2025 759.5 KB Genmab H1 2025 Financial Results Presentation 1.1 MB Jun 9, 2025 8:00 AM EDT Goldman Sachs 46th Annual Global Healthcare Conference Listen to the webcast Jun 5, 2025 9:20 AM EDT 2025 Jefferies Global Healthcare Conference Listen to the webcast Jun 2, 2025 5:00 PM EDT Post-ASCO R&D Update On Monday, June 2 Genmab hosted a Post-ASCO R&D update with a focus on recent Rina-S data. This was not an official event of the ASCO Annual Meeting. Listen to the Webcast Supporting Materials Rina-S Update at ASCO 2025 2.8 MB May 8, 2025 Publication of the Interim Report for the First Quarter 2025 (after 5:00 PM CEST) On May 8, Genmab announced its financial results for the first quarter of 2025. Listen to the Webcast Supporting Materials Interim Report for the First Quarter of 2025 640.8 KB Genmab Q1 2025 Financial Results Presentation 1.5 MB Mar 12, 2025 Annual General Meeting 2025 The Annual General Meeting 2025 took place on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark. Learn more. Mar 10, 2025 5:00 PM CET Genmab's Investor Call Regarding HexaBody-CD38 Listen to the Webcast Replay Supporting Materials Investor Call Regarding HexaBody-CD38_March 10, 2025 977.2 KB Mar 3, 2025 1:50 PM EST TD Cowen 45th Annual Health Care Conference Listen to the webcast Feb 12, 2025 Publication of the Annual Report for 2024 (after 5:00 PM CET) On February 12, Genmab announced its full-year financial results for 2024. Listen to the webcast Supporting Materials Genmab 2024 Annual Report 6.5 MB Genmab 2024 Full Year Financial Results Presentation 1.2 MB Jan 28, 2025 Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors Jan 14, 2025 from 3:00 PM to 3:40 PM PST 43rd Annual J.P. Morgan Healthcare Conference Link to webcast Supporting Materials Genmab_JP Morgan 2025_Final_Public.pdf 1.1 MB Dec 31, 2024 Financial Calendar Year End Dec 11, 2024 5:00 PM CET 2024 R&D Update and ASH Data Review Genmab hosted its 2024 R&D Update and ASH Data Review virtually on Wednesday, December 11, 2024.This meeting was not an official program of the ASH Annual Meeting. Listen to the webcast replay Supporting Materials Genmab R&D Update and ASH Data Review - December 2024 3.3 MB Dec 3, 2024 8:30 PM CET Citi’s 2024 Global Healthcare Conference Fireside Chat with Chief Financial Officer Anthony Pagano. Listen to Webcast Nov 6, 2024 Publication of the Interim Report for the First Nine Months 2024 (after 5:00 PM CET) On November 6, Genmab announced its financial results for the first nine months of 2024. Supporting Materials Interim Report for the First Nine Months of 2024 1.5 MB Genmab First Nine Months 2024 Financial Results Presentation 4.1 MB Aug 8, 2024 Publication of the Interim Report for the First Half 2024 (after 5:00 PM CEST) On August 8, Genmab announced its financial results for the first six months of 2024. Replay the webcast Supporting Materials Interim Report for the First Half of 2024 1.3 MB Genmab First Half 2024 Financial Results Presentation 4.6 MB Jun 3, 2024 9:00 AM CDT Virtual mid- to late-stage pipeline update at ASCO 2024 On Monday, June 3 Genmab held a review of data presented at ASCO from its mid- to late-stage pipeline. This meeting was not an official program of the ASCO Annual Meeting. Supporting Materials Genmab's Virtual mid- to late-stage pipeline update at ASCO 2024 963.7 KB May 2, 2024 Publication of the Interim Report for the First Quarter 2024 (after 5:00 PM CEST) Supporting Materials Genmab Q1 2024 Financial Results Presentation 4.1 MB Interim Report for the First Quarter of 2024 1.3 MB Mar 13, 2024 Annual General Meeting 2024 Feb 14, 2024 Publication of the Annual Report for 2023 (after 5:00 PM CET) Supporting Materials Genmab 2023 Full Year Financial Results Presentation 5 MB Jan 30, 2024 Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors
Aug 6, 2026 Publication of the Interim Report for the First Half 2026 (after 5:00 PM CEST) Genmab will publish its Interim Report for the First Half 2026 on August 6, 2026, after 5:00 pm CEST.A conference call to discuss Genmab’s Second Quarter 2026 Financial Results will be held the same day at 6:00 pm CEST / 12:00 pm EDT.Register for the call.To join the call please use the registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN. Listen to the webcast
May 7, 2026 Publication of the Interim Report for the First Quarter 2026 (after 5:00 PM CEST) Genmab held a conference call to discuss its Q1 2026 financial results on May 7, 2026. Listen to the webcast replay Supporting Materials Interim Report for the First Quarter of 2026 769.2 KB Genmab First Quarter 2026 Financial Results Presentation 1 MB
Mar 19, 2026 Annual General Meeting 2026 The Annual General Meeting 2026 will take place on Thursday, March 19, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark. Register here.
Feb 17, 2026 Publication of the Annual Report for 2025 (after 5:00 PM CET) Genmab will hold a conference call to discuss its 2025 financial results at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST on February 17, 2026 Listen to the webcast Supporting Materials Genmab 2025 Annual Report 12.7 MB Genmab 2025 Full Year Financial Results Presentation 1.1 MB
Jan 13, 2026 3:45 PM PST 44th Annual J.P. Morgan Healthcare Conference Listen to the webcast Supporting Materials JP Morgan 2026 Presentation 924.6 KB
Dec 11, 2025 11:00 AM EST 2025 R&D Update and ASH Data Review Genmab hosted its 2025 R&D Update and ASH Data Review virtually on Thursday, December 11, 2025.This meeting was not an official program of the ASH Annual Meeting. Listen to the webcast replay Supporting Materials Genmab R&D Update and ASH Data Review - December 2025 2 MB
Nov 19, 2025 1:00 PM CET Jefferies Healthcare Conference Fireside Chat with Chief Executive Officer, Jan van de Winkel, and Chief Financial Officer, Anthony Pagano. Listen to Webcast
Nov 6, 2025 Publication of the Interim Report for the First Nine Months 2025 (after 5:00 PM CET) Listen to the webcast replay Supporting Materials Interim Report for the First Nine Months of 2025 675.1 KB Genmab First Nine Months 2025 Financial Results Presentation 1.1 MB
Sep 29, 2025 7:00 AM EDT Genmab's Proposed Acquisition of Merus Listen to the Webcast Replay Supporting Materials Genmab’s Proposed Acquisition of Merus_September 29, 2025 1.1 MB
Sep 9, 2025 7:45 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat with Chief Executive Officer Jan van de Winkel and Chief Financial Officer Anthony Pagano. Listen to the webcast
Aug 7, 2025 Publication of the Interim Report for the First Half 2025 (after 5:00 PM CEST) On August 7, Genmab announced its financial results for the first half of 2025. Listen to the webcast Supporting Materials Interim Report for the First Half of 2025 759.5 KB Genmab H1 2025 Financial Results Presentation 1.1 MB
Jun 2, 2025 5:00 PM EDT Post-ASCO R&D Update On Monday, June 2 Genmab hosted a Post-ASCO R&D update with a focus on recent Rina-S data. This was not an official event of the ASCO Annual Meeting. Listen to the Webcast Supporting Materials Rina-S Update at ASCO 2025 2.8 MB
May 8, 2025 Publication of the Interim Report for the First Quarter 2025 (after 5:00 PM CEST) On May 8, Genmab announced its financial results for the first quarter of 2025. Listen to the Webcast Supporting Materials Interim Report for the First Quarter of 2025 640.8 KB Genmab Q1 2025 Financial Results Presentation 1.5 MB
Mar 12, 2025 Annual General Meeting 2025 The Annual General Meeting 2025 took place on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark. Learn more.
Mar 10, 2025 5:00 PM CET Genmab's Investor Call Regarding HexaBody-CD38 Listen to the Webcast Replay Supporting Materials Investor Call Regarding HexaBody-CD38_March 10, 2025 977.2 KB
Feb 12, 2025 Publication of the Annual Report for 2024 (after 5:00 PM CET) On February 12, Genmab announced its full-year financial results for 2024. Listen to the webcast Supporting Materials Genmab 2024 Annual Report 6.5 MB Genmab 2024 Full Year Financial Results Presentation 1.2 MB
Jan 28, 2025 Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors
Jan 14, 2025 from 3:00 PM to 3:40 PM PST 43rd Annual J.P. Morgan Healthcare Conference Link to webcast Supporting Materials Genmab_JP Morgan 2025_Final_Public.pdf 1.1 MB
Dec 11, 2024 5:00 PM CET 2024 R&D Update and ASH Data Review Genmab hosted its 2024 R&D Update and ASH Data Review virtually on Wednesday, December 11, 2024.This meeting was not an official program of the ASH Annual Meeting. Listen to the webcast replay Supporting Materials Genmab R&D Update and ASH Data Review - December 2024 3.3 MB
Dec 3, 2024 8:30 PM CET Citi’s 2024 Global Healthcare Conference Fireside Chat with Chief Financial Officer Anthony Pagano. Listen to Webcast
Nov 6, 2024 Publication of the Interim Report for the First Nine Months 2024 (after 5:00 PM CET) On November 6, Genmab announced its financial results for the first nine months of 2024. Supporting Materials Interim Report for the First Nine Months of 2024 1.5 MB Genmab First Nine Months 2024 Financial Results Presentation 4.1 MB
Aug 8, 2024 Publication of the Interim Report for the First Half 2024 (after 5:00 PM CEST) On August 8, Genmab announced its financial results for the first six months of 2024. Replay the webcast Supporting Materials Interim Report for the First Half of 2024 1.3 MB Genmab First Half 2024 Financial Results Presentation 4.6 MB
Jun 3, 2024 9:00 AM CDT Virtual mid- to late-stage pipeline update at ASCO 2024 On Monday, June 3 Genmab held a review of data presented at ASCO from its mid- to late-stage pipeline. This meeting was not an official program of the ASCO Annual Meeting. Supporting Materials Genmab's Virtual mid- to late-stage pipeline update at ASCO 2024 963.7 KB
May 2, 2024 Publication of the Interim Report for the First Quarter 2024 (after 5:00 PM CEST) Supporting Materials Genmab Q1 2024 Financial Results Presentation 4.1 MB Interim Report for the First Quarter of 2024 1.3 MB
Feb 14, 2024 Publication of the Annual Report for 2023 (after 5:00 PM CET) Supporting Materials Genmab 2023 Full Year Financial Results Presentation 5 MB
Jan 30, 2024 Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors